News & Perspective

Jul 30, 2009

Jul 30, 2009

Packaging, not yield, may be problem for nasal-spray H1N1 vaccine

(CIDRAP News) – While most vaccine manufacturers have reaped below-average crops of H1N1 influenza vaccine virus from the eggs in which they're grown, MedImmune Inc. has a different problem: high virus yields, but a potential shortage of the devices used to spray the vaccine into the nose.

Jul 29, 2009

Jul 29, 2009

ACIP targets up to 159 million Americans for H1N1 vaccination

(CIDRAP News) – The top US advisory panel on immunizations recommended today that groups totaling up to 159 million people be targeted for vaccination against the pandemic H1N1 influenza virus but that a narrower population of about 41 million have priority if initial supplies are short.

Jul 23, 2009

Jul 23, 2009

FDA may use strain change model for evaluating H1N1 vaccines

(CIDRAP News) – The Food and Drug Administration (FDA) may review vaccines for the novel H1N1 influenza virus the same way it evaluates the annual updates of seasonal flu vaccines, which would probably lead to faster FDA approval than occurs with brand-new products, an FDA official said in the wake of an FDA advisory committee meeting today.

May 26, 2009

May 26, 2009

Companies receive HHS orders for novel flu vaccine

(CIDRAP News) –Two vaccine companies, Sanofi Pasteur and GlaxoSmithKline, recently announced they received their first orders from the US government for a vaccine and adjuvant to protect the country against the novel H1N1 virus.

May 06, 2009

May 06, 2009

FDA approves new vaccine facility

(CIDRAP News) –The US Food and Drug Administration (FDA) today announced approval of a new influenza vaccine manufacturing facility in Pennsylvania that could be used to produce a vaccine against the novel influenza H1N1 (swine flu) virus.

Feb 12, 2009

Feb 12, 2009

US court rejects vaccines-autism link

(CIDRAP News) – In a ruling that aligns with numerous research studies, a special federal court today rejected claims by three sets of parents that vaccines caused their children's autism.

The US Court of Federal Claims ruled against claims that autism was triggered by measles-mumps-rubella (MMR) vaccine or by MMR vaccine in combination with vaccines containing thimerosal.

Feb 03, 2009

Feb 03, 2009

Experts weigh new H5N1 vaccine strategies

(CIDRAP News) – At an Infectious Diseases Society of America (IDSA) symposium in Washington, DC, today on seasonal and pandemic influenza, a group of experts fielded questions from reporters on some of the new trends and emerging issues, including prepandemic strategies for H5N1 avian influenza vaccines, now that some countries are stockpiling them.

Jan 15, 2009

Jan 15, 2009

Novartis gets US contract for cell-based flu vaccine plant

(CIDRAP News) – The US government has awarded Novartis a $487 million contract to help build a plant in North Carolina that the company says will be capable of producing 150 million doses of cell-based pandemic influenza vaccine within 6 months after the start of a pandemic.

Jan 09, 2009

Jan 09, 2009

HHS reports progress on cell-based pandemic vaccines

(CIDRAP News) – In a progress report on federal pandemic influenza planning efforts, the US Department of Health and Human Services (HHS) says several companies working under federal contracts are on track to develop cell culture–based pandemic flu vaccines.

Dec 04, 2008

Dec 04, 2008

HHS releases draft of national vaccine plan

(CIDRAP News) – The US Department of Health and Human Services (HHS) yesterday released a draft of its national vaccine strategy, which, once finalized, will serve as the federal government's game plan for guiding its policy decisions on infectious disease vaccine.

The 85-page report, dated Nov 26, is intended to update the nation's vaccine plan, which was mandated by Congress and first released in 1994, according to the report.

Pages

by Topic

by country

by organization

Newsletter Sign-up

Get CIDRAP news and other free newsletters.

Sign up now»

OUR UNDERWRITERS

Unrestricted financial support provided by

Bentson Foundation Gilead 
Grant support for ASP provided by


bioMérieux

  Become an underwriter»